长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌疗效观察

目的:探索长春瑞滨(NVB)+奥沙利铂(N0方案)与长春瑞滨+顺铂(NP方案)治疗晚期非小细胞肺癌的疗效.方法:59例非小细胞肺癌患者随机分为治疗组29例和对照组30例.治疗组给予长春瑞滨+奥沙利铂治疗;对照组给予长春瑞滨+顺铂治疗,两组均21天为1个周期,用药2周期.结果:总有效率治疗组为41.1%,对照组为46.7%(P>0.05).不良反应以白细胞减少、恶心、呕吐以及周围神经炎为主.Ⅲ～Ⅳ度的恶心、呕吐,肾功能损害及心功能不全主要发生在对照组,周围神经炎主要发生在治疗组(P<0.05).结论:长春瑞滨+奥沙利铂治疗晚期非小细胞肺癌疗效确切,患者耐受性良好,为晚期非小细胞肺癌的治疗提供了一种新的选择,更适宜老年及心肺功能不全的患者.

Vinorelbine combined with oxaliplatin in treatment of advanced non-small cell lung cancer

Objective：To evaluate the efficacy and side-effects in advanced non-small cell lung cancer（NSCLC） treated with vinorelbine plus oxaliplatin or vinorelbine plus cisplatin.Methods：59 patients with advanced NSCLC diagnosed by pathology or cytology were randomly divided into study group（NVB＋L-OHP,n=29） and control group（NVB＋DDP,n=30）.All patients received two cycles,21 d as a cycle.Results：The overall response rate was 41.4% in the study group and 46.7% in the control group（P〉0.05）.The main toxicities included leukopenia,nausea/vomiting and peripheral neuritis.Grade Ⅲ,Ⅳnausea/vomiting renal toxicity and cardiac insufficiency occurred more frequently in the control group,peripheral neuritis occurred more frequently in the study group（P〈0.05）.Conclusion：Due to good efficacy and tolerability,the NO（NVB＋L-OHP） regimen offers a new candidate for treating advanced NSCLC,especially for older patients and the patients with cardiopulmonary insufficiency.